Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Eguchi S, Kimura K, Kageyama K, Tani N, Tanaka R, Nishio K, Shinkawa H, Ohira GO, Amano R, Tanaka S, Yamamoto A, Takemura S, Yashiro M, Kubo S. Optimal Organ for Patient-derived Xenograft Model in Pancreatic Cancer and Microenvironment that Contributes to Success. Anticancer Res. 2022 May; 42(5):2395-2404.
-
Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, Moore M, Michael J, Driscoll C, Pulido J, Swanson E, Kennedy R, Coffey M, Loghmani H, Sanchez-Perez L, Olivier G, Harrington K, Pandha H, Melcher A, Diaz RM, Vile RG. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. 2022 04 13; 14(640):eabn2231.
-
Woess K, Sun Y, Morio H, Stierschneider A, Kaufmann A, Hainzl S, Trattner L, Kocher T, Tockner B, Leb-Reichl V, Steiner M, Brachtl G, South AP, Bauer JW, Reichelt J, Furihata T, Wally V, Koller U, Piñón Hofbauer J, Guttmann-Gruber C. Evaluating a Targeted Cancer Therapy Approach Mediated by RNA trans-Splicing In Vitro and in a Xenograft Model for Epidermolysis Bullosa-Associated Skin Cancer. Int J Mol Sci. 2022 Jan 05; 23(1).
-
Sato K, Padgaonkar AA, Baker SJ, Cosenza SC, Rechkoblit O, Subbaiah DRCV, Domingo-Domenech J, Bartkowski A, Port ER, Aggarwal AK, Ramana Reddy MV, Irie HY, Reddy EP. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Nat Commun. 2021 08 03; 12(1):4671.
-
Staquicini FI, Hajitou A, Driessen WH, Proneth B, Cardó-Vila M, Staquicini DI, Markosian C, Hoh M, Cortez M, Hooda-Nehra A, Jaloudi M, Silva IT, Buttura J, Nunes DN, Dias-Neto E, Eckhardt B, Ruiz-Ramírez J, Dogra P, Wang Z, Cristini V, Trepel M, Anderson R, Sidman RL, Gelovani JG, Cristofanilli M, Hortobagyi GN, Bhujwalla ZM, Burley SK, Arap W, Pasqualini R. Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer. Elife. 2021 06 01; 10.
-
Liu X, Adorno-Cruz V, Chang YF, Jia Y, Kawaguchi M, Dashzeveg NK, Taftaf R, Ramos EK, Schuster EJ, El-Shennawy L, Patel D, Zhang Y, Cristofanilli M, Liu H. EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer. Theranostics. 2021; 11(13):6632-6643.
-
Tewary P, Brooks AD, Xu YM, Wijeratne EMK, Babyak AL, Back TC, Chari R, Evans CN, Henrich CJ, Meyer TJ, Edmondson EF, de Aquino MTP, Kanagasabai T, Shanker A, Gunatilaka AAL, Sayers TJ. Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. Cancer Res. 2021 06 15; 81(12):3374-3386.
-
Ali M, Zuzga DS, Pitari GM. Differential Ser phosphorylation of vasodilator-stimulated phosphoprotein regulates colon tumor formation and growth. Life Sci. 2021 Jan 01; 264:118671.
-
Yu J, Yusoff PAM, Woutersen DTJ, Goh P, Harmston N, Smits R, Epstein DM, Virshup DM, Madan B. The Functional Landscape of Patient-Derived RNF43 Mutations Predicts Sensitivity to Wnt Inhibition. Cancer Res. 2020 12 15; 80(24):5619-5632.
-
Harrison DJ, Gill JD, Roth ME, Zhang W, Teicher B, Erickson S, Gatto G, Kurmasheva RT, Houghton PJ, Smith MA, Kolb EA, Gorlick R. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatr Blood Cancer. 2020 06; 67(6):e28222.